Thompson E W, Reich R, Shima T B, Albini A, Graf J, Martin G R, Dickson R B, Lippman M E
Laboratory of Developmental Biology and Anomalies, National Institute of Dental Research, Bethesda, Maryland 20892.
Cancer Res. 1988 Dec 1;48(23):6764-8.
Estrogen increases the ability of the estrogen-dependent MCF-7 human breast cancer cell line to both proliferate and invade through an artificial basement membrane. In studying the response of MCF-7 cells to various antiestrogens, we found that 4-hydroxytamoxifen and tamoxifen inhibited cell proliferation but increased their invasiveness. In contrast, the structurally unrelated benzothiophene antiestrogens, LY117018 and LY156758, were potent antiproliferative agents which did not stimulate invasiveness. The differential effects of these antiestrogenic agents on invasion correlated with changes in production of collagenase IV, while no significant change was seen in the chemotactic activity of the cells. Invasiveness was increased by 17 beta-estradiol or 4-hydroxytamoxifen after a few hours of treatment and was rapidly lost when 17 beta-estradiol was withdrawn. Stimulation of invasiveness with 17 beta-estradiol was blocked by the antiestrogen, LY117018. Cells from the MDA-MB-231 line which lacks estrogen receptors were not affected by estrogen or antiestrogen in terms of proliferation or invasion. These studies indicate that the invasiveness of MCF-7 cells is regulated by antiestrogens through the estrogen receptor and may be mediated by collagenase IV activity. Antiestrogens which reduce both the proliferation and invasiveness of these cells may be interesting new candidates for clinical application.
雌激素可增强雌激素依赖的MCF - 7人乳腺癌细胞系通过人工基底膜进行增殖和侵袭的能力。在研究MCF - 7细胞对各种抗雌激素药物的反应时,我们发现4 - 羟基他莫昔芬和他莫昔芬可抑制细胞增殖,但会增加其侵袭性。相比之下,结构不相关的苯并噻吩类抗雌激素药物LY117018和LY156758是强效的抗增殖剂,不会刺激侵袭性。这些抗雌激素药物对侵袭的不同作用与IV型胶原酶产生的变化相关,而细胞的趋化活性未见明显变化。用17β - 雌二醇或4 - 羟基他莫昔芬处理数小时后侵袭性增加,当撤去17β - 雌二醇时侵袭性迅速丧失。抗雌激素药物LY117018可阻断17β - 雌二醇对侵袭性的刺激。缺乏雌激素受体的MDA - MB - 231细胞系的细胞在增殖或侵袭方面不受雌激素或抗雌激素的影响。这些研究表明,MCF - 7细胞的侵袭性受抗雌激素药物通过雌激素受体调控,可能由IV型胶原酶活性介导。能同时降低这些细胞增殖和侵袭性的抗雌激素药物可能是临床应用中有趣的新候选药物。